Phenylalanine content and PKU
Advantame is metabolised to release phenylalanine, the same amino acid produced by aspartame. People with phenylketonuria (PKU) lack the enzyme to break down phenylalanine safely, so accumulation causes neurological harm. UK food law mandates a 'contains a source of phenylalanine' declaration on any product containing advantame. For the general population the quantities released at permitted use levels are nutritionally insignificant.
Advantame yields phenylalanine on hydrolysis, triggering the same mandatory PKU labelling requirement as aspartame under UK and EU food information law.
2014RegulatoryUK Food Information Regulations 2014 / EU Regulation 1169/2011 Annex II
Animal safety studies and ADI
EFSA's Panel on Food Additives reviewed the full toxicology dossier for advantame in 2013. Studies covering genotoxicity, carcinogenicity, reproductive toxicity, and developmental toxicity were assessed. No genotoxicity or carcinogenicity signal was found. The key effect used to set the safety limit was maternal gastrointestinal disturbance in a rabbit developmental study at high doses. EFSA set an acceptable daily intake of 5 milligrams per kilogram of body weight per day, derived by applying a 100-fold safety factor to that no-effect dose.
EFSA found no concern for genotoxicity or carcinogenicity in its comprehensive review of advantame toxicology studies.
2013Regulatory reviewEFSA ANS Panel, Scientific Opinion on the safety of advantame, EFSA Journal 2013;11(7):3301
The Panel established an ADI of 5mg/kg body weight/day, based on a NOAEL of 500mg/kg body weight/day for maternal toxicity in rabbits and a 100-fold uncertainty factor.
2013AnimalEFSA ANS Panel, Scientific Opinion on the safety of advantame, EFSA Journal 2013;11(7):3301
Conservative exposure estimates for high-consuming adults and children were well below the established ADI at the proposed use levels.
2013Regulatory reviewEFSA ANS Panel, Scientific Opinion on the safety of advantame, EFSA Journal 2013;11(7):3301
Gut microbiome and sweetener research
Broader research into high-intensity sweeteners has raised questions about whether regular consumption affects gut bacteria or insulin signalling, though this evidence is largely observational or based on other sweeteners. Advantame-specific data in humans is limited. Most studies on sweetener-microbiome interactions have used saccharin, sucralose, or aspartame, and findings have not been directly confirmed for advantame.
A 2022 randomised trial found that certain non-sugar sweeteners, including saccharin and sucralose, altered gut microbiome composition and glucose tolerance in some participants, though advantame was not included in the study.
2022RCTSuez et al., Cell, 2022